Fuller & Thaler Asset Management Inc. Purchases 708,312 Shares of Exelixis, Inc. (NASDAQ:EXEL)

Fuller & Thaler Asset Management Inc. increased its position in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 10.2% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 7,630,940 shares of the biotechnology company's stock after acquiring an additional 708,312 shares during the quarter. Exelixis comprises about 1.0% of Fuller & Thaler Asset Management Inc.'s holdings, making the stock its 15th biggest holding. Fuller & Thaler Asset Management Inc. owned 2.67% of Exelixis worth $254,110,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the company. Vanguard Group Inc. grew its holdings in shares of Exelixis by 0.4% during the fourth quarter. Vanguard Group Inc. now owns 29,429,252 shares of the biotechnology company's stock worth $979,994,000 after purchasing an additional 121,750 shares in the last quarter. LSV Asset Management grew its stake in Exelixis by 0.8% in the 4th quarter. LSV Asset Management now owns 8,169,847 shares of the biotechnology company's stock worth $272,056,000 after buying an additional 67,470 shares in the last quarter. Invesco Ltd. increased its holdings in shares of Exelixis by 308.1% in the 4th quarter. Invesco Ltd. now owns 3,975,241 shares of the biotechnology company's stock worth $132,376,000 after buying an additional 3,001,204 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its position in shares of Exelixis by 104.4% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 3,159,395 shares of the biotechnology company's stock valued at $105,208,000 after buying an additional 1,613,482 shares in the last quarter. Finally, FMR LLC lifted its holdings in shares of Exelixis by 19.7% during the 4th quarter. FMR LLC now owns 2,947,599 shares of the biotechnology company's stock worth $98,155,000 after acquiring an additional 485,527 shares during the last quarter. Hedge funds and other institutional investors own 85.27% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on EXEL shares. Guggenheim restated a "buy" rating and set a $42.00 price target on shares of Exelixis in a research report on Wednesday, February 12th. Truist Financial boosted their target price on Exelixis from $42.00 to $43.00 and gave the stock a "buy" rating in a research report on Monday, January 27th. Wells Fargo & Company reiterated a "market outperform" rating on shares of Exelixis in a research report on Thursday, April 17th. Royal Bank of Canada boosted their price objective on shares of Exelixis from $38.00 to $40.00 and gave the stock an "outperform" rating in a report on Thursday, March 13th. Finally, Piper Sandler increased their target price on shares of Exelixis from $37.00 to $38.00 and gave the company an "overweight" rating in a report on Wednesday, February 12th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Exelixis has a consensus rating of "Moderate Buy" and a consensus target price of $37.59.

Insiders Place Their Bets

In other news, Director Jack L. Wyszomierski sold 8,768 shares of the stock in a transaction on Friday, February 28th. The stock was sold at an average price of $37.80, for a total value of $331,430.40. Following the sale, the director now directly owns 356,605 shares of the company's stock, valued at approximately $13,479,669. This represents a 2.40 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Patrick J. Haley sold 52,636 shares of Exelixis stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $36.98, for a total value of $1,946,479.28. Following the completion of the transaction, the executive vice president now directly owns 303,310 shares of the company's stock, valued at approximately $11,216,403.80. This represents a 14.79 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 140,343 shares of company stock worth $5,177,234. 2.85% of the stock is currently owned by company insiders.

Exelixis Stock Performance

Shares of NASDAQ EXEL traded up $0.65 during midday trading on Monday, hitting $38.08. 1,053,757 shares of the company traded hands, compared to its average volume of 2,177,861. Exelixis, Inc. has a 12-month low of $20.14 and a 12-month high of $40.02. The firm has a market cap of $10.50 billion, a P/E ratio of 21.51, a P/E/G ratio of 1.13 and a beta of 0.57. The stock has a 50-day moving average price of $36.68 and a 200 day moving average price of $34.73.

Exelixis (NASDAQ:EXEL - Get Free Report) last released its earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 EPS for the quarter, missing analysts' consensus estimates of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%. As a group, equities analysts expect that Exelixis, Inc. will post 2.04 earnings per share for the current year.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.